Dyne Therapeutics, Inc. Proceeds from Stock Options Exercised
Dyne Therapeutics, Inc. (DYN) reported Proceeds from Stock Options Exercised of $2.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-07-29
- Dyne Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2026-06-30 was $737.00K, a 62.63% decline year-over-year.
- Dyne Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2026-03-31 was $1.31M, a 122.96% increase year-over-year.
- Dyne Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2025-12-31 was $3.37M, a 7.43% decline year-over-year.
- Dyne Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2025-09-30 was $2.07M, a 88.49% decline year-over-year.
- Dyne Therapeutics, Inc. proceeds from stock options exercised for fiscal 2025 was $8.00M, a 78.29% decline from fiscal 2024.
- Dyne Therapeutics, Inc. proceeds from stock options exercised for fiscal 2024 was $36.84M, a 1786.53% increase from fiscal 2023.
- Dyne Therapeutics, Inc. proceeds from stock options exercised for fiscal 2023 was $1.95M, a 269.19% increase from fiscal 2022.
- Dyne Therapeutics, Inc. proceeds from stock options exercised for fiscal 2022 was $529.00K, a 9.42% decline from fiscal 2021.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $737.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $2.05M 10-Q · filed 2026-07-29 | $5.41M derived: sum of 3 quarters · filed 2026-07-29 | $7.49M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $1.31M 10-Q · filed 2026-05-11 | $4.68M derived: sum of 2 quarters · filed 2026-05-11 | $6.75M derived: sum of 3 quarters · filed 2026-05-11 | $8.72M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $5.44M derived: sum of 2 quarters · filed 2026-03-02 | $7.41M derived: sum of 3 quarters · filed 2026-07-29 | $8.00M 10-K · filed 2026-03-02 |
| 2025-09-30 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.04M derived: sum of 2 quarters · filed 2026-07-29 | $4.63M 10-Q · filed 2025-11-05 | $8.27M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $1.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $2.56M 10-Q · filed 2026-07-29 | $6.20M derived: sum of 3 quarters · filed 2026-07-29 | $24.20M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $588.00K 10-Q · filed 2026-05-11 | $4.22M derived: sum of 2 quarters · filed 2026-05-11 | $22.23M derived: sum of 3 quarters · filed 2026-05-11 | $26.52M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $3.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $21.64M derived: sum of 2 quarters · filed 2026-03-02 | $25.93M derived: sum of 3 quarters · filed 2026-03-02 | $36.84M 10-K · filed 2026-03-02 |
| 2024-09-30 | $18.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $22.29M derived: sum of 2 quarters · filed 2025-11-05 | $33.21M 10-Q · filed 2025-11-05 | $33.36M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $4.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | $15.20M 10-Q · filed 2025-07-28 | $15.35M derived: sum of 3 quarters · filed 2026-03-02 | $15.80M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $10.92M 10-Q · filed 2025-05-08 | $11.06M derived: sum of 2 quarters · filed 2026-03-02 | $11.52M derived: sum of 3 quarters · filed 2026-03-02 | $12.28M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $602.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.37M derived: sum of 3 quarters · filed 2026-03-02 | $1.95M 10-K · filed 2026-03-02 |
| 2023-09-30 | $454.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.22M derived: sum of 2 quarters · filed 2024-11-12 | $1.80M 10-Q · filed 2024-11-12 | $2.15M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $764.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.35M 10-Q · filed 2024-08-12 | $1.69M derived: sum of 3 quarters · filed 2025-02-27 | $1.76M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $587.00K 10-Q · filed 2024-05-02 | $929.00K derived: sum of 2 quarters · filed 2025-02-27 | $999.00K derived: sum of 3 quarters · filed 2025-02-27 | $1.10M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $342.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $412.00K derived: sum of 2 quarters · filed 2025-02-27 | $511.00K derived: sum of 3 quarters · filed 2025-02-27 | $529.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $70.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | $169.00K derived: sum of 2 quarters · filed 2023-10-30 | $187.00K 10-Q · filed 2023-10-30 | $276.00K derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-06-30 | $99.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $117.00K 10-Q · filed 2023-08-03 | $206.00K derived: sum of 3 quarters · filed 2023-08-03 | $663.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $18.00K 10-Q · filed 2023-05-11 | $107.00K derived: sum of 2 quarters · filed 2023-05-11 | $564.00K derived: sum of 3 quarters · filed 2023-05-11 | $589.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $546.00K derived: sum of 2 quarters · filed 2023-03-02 | $571.00K derived: sum of 3 quarters · filed 2023-03-02 | $584.00K 10-K · filed 2023-03-02 |
| 2021-09-30 | $457.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $482.00K derived: sum of 2 quarters · filed 2022-11-03 | $495.00K 10-Q · filed 2022-11-03 | $501.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $38.00K 10-Q · filed 2022-08-04 | $44.00K derived: sum of 3 quarters · filed 2022-08-04 | |
| 2021-03-31 | $13.00K 10-Q · filed 2022-05-02 | $19.00K derived: sum of 2 quarters · filed 2022-05-02 | ||
| 2020-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $30.00K 10-K · filed 2022-03-10 | ||
| 2020-09-30 | $24.00K 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |